首页> 美国卫生研究院文献>Journal of Hematology Oncology >Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
【2h】

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

机译:自体串联与自体串联同种异体造血细胞移植在新诊断多发性骨髓瘤患者中的比较疗效:随机对照试验的系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDespite advances in understanding of clinical, genetic, and molecular aspects of multiple myeloma (MM) and availability of more effective therapies, MM remains incurable. The autologous-allogeneic (auto-allo) hematopoietic cell transplantation (HCT) strategy is based on combining cytoreduction from high-dose (chemo- or chemoradio)-therapy with adoptive immunotherapy. However, conflicting results have been reported when an auto-allo HCT approach is compared to tandem autologous (auto-auto) HCT. A previously published meta-analysis has been reported; however, it suffers from serious methodological flaws.
机译:背景技术尽管在了解多发性骨髓瘤(MM)的临床,遗传和分子方面取得了进步,并且可获得更有效的疗法,但MM仍然是无法治愈的。自体-异体(自体)造血细胞移植(HCT)策略是基于将大剂量(化学或化学放疗)疗法中的细胞减少与过继免疫疗法相结合。但是,当将自动alter HCT方法与串联自体(auto-auto)HCT相比较时,已经报告了矛盾的结果。已经报道了以前发表的荟萃分析。但是,它存在严重的方法缺陷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号